Management of adverse events associated with idelalisib treatment: expert panel opinion.

Published

Journal Article (Review)

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. An expert panel was convened to review the pathology of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy. This article provides an overview of idelalisib TEAEs reported in clinical trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis. For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or intravenous steroid therapy.

Full Text

Duke Authors

Cited Authors

  • Coutré, SE; Barrientos, JC; Brown, JR; de Vos, S; Furman, RR; Keating, MJ; Li, D; O'Brien, SM; Pagel, JM; Poleski, MH; Sharman, JP; Yao, N-S; Zelenetz, AD

Published Date

  • 2015

Published In

Volume / Issue

  • 56 / 10

Start / End Page

  • 2779 - 2786

PubMed ID

  • 25726955

Pubmed Central ID

  • 25726955

Electronic International Standard Serial Number (EISSN)

  • 1029-2403

Digital Object Identifier (DOI)

  • 10.3109/10428194.2015.1022770

Language

  • eng

Conference Location

  • United States